. . . . . . . . . . . . . . . . "TextLocation" . "Results" . "a(CHEBIID:59826) -> p(HGNC:JAK2,pmod(P,Y))" . "Approximately 2000 hand curated statements drawn from 57 PubMeds." . "Copyright (c) 2011-2012, Selventa. All Rights Reserved." . "BEL Framework Small Corpus Document" . "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License" . . "1.6" . "In the absence of R5020 pretreatment, JAK2 is immunoprecipitated with the anti-phosphotyrosine\nantibody only following EGF treatment (lane 2). Note that JAK2 is\nnot present in phosphotyrosine immunoprecipitates after 1 h of R5020 treatment (lane\n1). However, JAK2 is immunoprecipitated with the anti-phosphotyrosine antibody\nas efficiently after 48 h of R5020 treatment (lane 4) as with EGF treatment\n(lane 5)." . . "support@belframework.org" . "Selventa" . . . . "2014-07-03T14:29:30.799+02:00"^^ . . .